Nasim Kheshtchin

Nasim Kheshtchin

Auto-generated profile, based on publicly available information

Nasim Kheshtchin

Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Journal of Controlled Release
Verified
Journal Article
Closed access
FJFarhad Jadidi-Niaragh
Farhad Jadidi-Niaragh
FAFatemeh Atyabi
Fatemeh Atyabi
ARAli Rastegari
Ali Rastegari
NKNasim Kheshtchin
Nasim Kheshtchin
SASamaneh Arab
Samaneh Arab
JHJamshid Hadjati
Jamshid Hadjati

6 August 2016 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
NKNasim Kheshtchin
Nasim Kheshtchin
SASamaneh Arab
Samaneh Arab
MAMaryam Ajami
Maryam Ajami
RMReza Mirzaei
Reza Mirzaei
MAMahboubeh Ashourpour
Mahboubeh Ashourpour
JHJamshid Hadjati
Jamshid Hadjati

5 January 2016 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
FJFarhad Jadidi-Niaragh
Farhad Jadidi-Niaragh
FAFatemeh Atyabi
Fatemeh Atyabi
ARAli Rastegari
Ali Rastegari
EMEsmail Mollarazi
Esmail Mollarazi
MKMelika Kiani
Melika Kiani
FSFazel Shokri
Fazel Shokri

28 March 2017 in Tumor Biology
Verified
Journal Article
Open access
SASamaneh Arab
Samaneh Arab
NKNasim Kheshtchin
Nasim Kheshtchin
MAMaryam Ajami
Maryam Ajami
MAMahbubeh Ashurpoor
Mahbubeh Ashurpoor
ASAida Safvati
Aida Safvati
JHJamshid Hadjati
Jamshid Hadjati
Dendritic cells are important in initiating immune responses; therefore, a range of dendritic cell–based approaches have been established to induce immune response against cancer cells. However, the presence of immunosuppressive mediators such as adenosine in the tumor microenvironment reduces the efficacy of dendritic cell–based cancer immunotherapy. In this study, we investigated whether blockade of the A2A adenosine receptor with a selective antagonist and a CD73 inhibitor may increase the efficacy of a dendritic cell–based cancer vaccine. According to the findings, this therapeutic combination reduced tumor growth, prolonged survival of tumor-bearing mice, and enhanced specific antitumor immune responses. Thus, we suggest that targeting cancer-derived adenosine improves the outcomes of dendritic cell–based cancer immunotherapy.

6 July 2010 in American Journal of Reproductive Immunology
Verified
Journal Article
Closed access
PDF file
NKNasim Kheshtchin
Nasim Kheshtchin
MGMarjan Gharagozloo
Marjan Gharagozloo
AAAlireza Andalib
Alireza Andalib
AGAtaollah Ghahiri
Ataollah Ghahiri
MMMohammad Reza Maracy
Mohammad Reza Maracy
ARAbbas Rezaei
Abbas Rezaei

19 November 2021 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
NKNasim Kheshtchin
Nasim Kheshtchin
JHJamshid Hadjati
Jamshid Hadjati